Menu
Back to User profile » Dr Donald Banerji
Papers published by Dr Donald Banerji:
Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients
Kostikas K, Mackay AJ, Vogelmeier CF, Frent SM, Gupta P, Banerji D, Patalano F, Pfister PJ, Wedzicha JA
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:1831-1838
Published Date: 28 July 2020
Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study
Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1125-1134
Published Date: 10 April 2018
The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1325-1337
Published Date: 4 May 2017
Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study
Wedzicha JA, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C, Patalano F, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:339-349
Published Date: 19 January 2017
Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study [Corrigendum]
Hashimoto S, Ikeuchi H, Murata S, Kitawaki T, Ikeda K, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:231-232
Published Date: 10 January 2017
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
Vogelmeier C, Zhong NS, Humphries MJ, Mezzi K, Fogel R, Bader G, Patalano F, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:3189-3197
Published Date: 14 December 2016
Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study
Hashimoto S, Ikeuchi H, Murata S, Kitawaki T, Ikeda K, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:2543-2551
Published Date: 11 October 2016
LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1015-1026
Published Date: 5 June 2015
Symptoms and impact of COPD assessed by an electronic diary in patients with moderate-to-severe COPD: psychometric results from the SHINE study
Kulich K, Keininger DL, Tiplady B, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:79-94
Published Date: 7 January 2015
Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Buhl R, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:287-288
Published Date: 19 March 2014
Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]
Dahl R, Jadayel D, Alagappan VKT, Chen H, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:85-86
Published Date: 16 January 2014
Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study
Dahl R, Jadayel D, Alagappan VKT, Chen H, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:501-508
Published Date: 17 October 2013
Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
Buhl R, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:729-741
Published Date: 26 October 2012